Top

Published in:

01-10-2019 | Colorectal Cancer | PRECLINICAL STUDIES

Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib

Authors: Titto Augustine, Radhashree Maitra, Jinghang Zhang, Jay Nayak, Sanjay Goel

Published in: Investigational New Drugs | Issue 5/2019

Summary

Intended to explore synthetic lethality and develop better combinatorial regimens, we screened colorectal cancer (CRC) cells using poly ADP-ribose (PAR) polymerase (PARP) inhibitors and cytotoxic agents. We studied four PARP inhibitors and three DNA-damaging agents, and their combinations using sulforhodamine B assay. Rucaparib demonstrated the greatest synergy with irinotecan, followed by olaparib and PJ34. Rucaparib and irinotecan was further subjected to detailed examination to determine combination index (CI) and underlying mechanism of action. Effectiveness and sequence dependence of this combination were assessed in microsatellite stable (MSS) and unstable (MSI) CRC and HCT116 isogenic cell lines. The degree of cell cycle arrest and apoptosis was determined by FACS. In vivo studies were performed to confirm efficacy of this combination. PAR levels in MSI and PARP expression in MSI and MSS cell lines were diminished upon combinatorial treatment. HCT116 isogenic cells revealed the importance of p21, p53 and PTEN in exerting synergy. In MSI cells, administration of rucaparib prior to irinotecan enhanced cytotoxicity compared to other strategies explored. FACS revealed S-phase arrest and increased late-stage apoptosis in MSS, and G2-M arrest and total and early-stage apoptosis in MSI cells. In in vivo murine xenograft models, a significant reduction in tumor volume and expression of Ki67, pancytokeratin and RPS6KB1, and increase in expression of caspase 3 were observed with the combination. In conclusion, among the various combinations studied, rucaparib plus irinotecan was the most synergistic one. Alterations in cell cycle arrest and apoptosis were dependent on MSI status in CRC cells.

Lin YL, Liau JY, Yu SC, Ou DL, Lin LI, Tseng LH, Chang YL, Yeh KH, Cheng AL (2012) KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells. PLoS One 7(11):e50701. https://doi.org/10.1371/journal.pone.0050701 CrossRefPubMedPubMedCentral

Peters GJ (2015) Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies. Ther Adv Med Oncol 7(6):340–356. https://doi.org/10.1177/1758834015603313 CrossRefPubMedPubMedCentral

Platell C, Ng S, O'Bichere A, Tebbutt N (2011) Changing management and survival in patients with stage IV colorectal cancer. Dis Colon Rectum 54(2):214–219. https://doi.org/10.1007/DCR.0b013e3182023bb0 CrossRefPubMed

Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33(1):9–23. https://doi.org/10.1016/j.ctrv.2006.09.006 CrossRef

Osoegawa A, Gills JJ, Kawabata S, Dennis PA (2017) Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib. Oncotarget 8(50):87044–87053. https://doi.org/10.18632/oncotarget.19667 CrossRefPubMedPubMedCentral

Wei H, Yu X (2016) Functions of PARylation in DNA damage repair pathways. Genomics Proteomics Bioinformatics 14(3):131–139. https://doi.org/10.1016/j.gpb.2016.05.001 CrossRefPubMedPubMedCentral

Dizdar O, Arslan C, Altundag K (2015) Advances in PARP inhibitors for the treatment of breast cancer. Expert Opin Pharmacother 16(18):2751–2758. https://doi.org/10.1517/14656566.2015.1100168 CrossRefPubMed

Munoz-Gamez JA, Martin-Oliva D, Aguilar-Quesada R, Canuelo A, Nunez MI, Valenzuela MT, Ruiz de Almodovar JM, De Murcia G, Oliver FJ (2005) PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J 386(Pt 1):119–125. https://doi.org/10.1042/BJ20040776 CrossRefPubMedPubMedCentral

Walsh C (2018) Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use. Minerva Ginecol 70(2):150–170. https://doi.org/10.23736/S0026-4784.17.04152-1 CrossRefPubMed

10.

Foucquier J, Guedj M (2015) Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect 3(3):e00149. https://doi.org/10.1002/prp2.149 CrossRefPubMedPubMedCentral

11.

Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y (2014) Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther 349(3):408–416. https://doi.org/10.1124/jpet.113.210146 CrossRefPubMedPubMedCentral

12.

Augustine TA, Baig M, Sood A, Budagov T, Atzmon G, Mariadason JM, Aparo S, Maitra R, Goel S (2015) Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. Br J Cancer 112(2):313–318. https://doi.org/10.1038/bjc.2014.561 CrossRefPubMed

13.

Gandhi JS, Goswami M, Sharma A, Tanwar P, Gupta G, Gupta N, Pasricha S, Mehta A, Singh S, Agarwal M, Gupta N (2017) Clinical impact of mismatch repair protein testing on outcome of early staged colorectal carcinomas. J Gastrointest Cancer 49:406–414. https://doi.org/10.1007/s12029-017-9954-5 CrossRef

14.

Shirasawa S, Furuse M, Yokoyama N, Sasazuki T (1993) Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260(5104):85–88CrossRef

15.

Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6):561–573. https://doi.org/10.1016/j.ccr.2005.05.014 CrossRefPubMed

16.

Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R, Mariadason JM (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68(6):1953–1961. https://doi.org/10.1158/0008-5472.CAN-07-5659 CrossRefPubMedPubMedCentral

17.

Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24(3):227–235. https://doi.org/10.1038/73432 CrossRefPubMed

18.

Samaraweera L, Adomako A, Rodriguez-Gabin A, McDaid HM (2017) A novel indication for panobinostat as a senolytic drug in NSCLC and HNSCC. Sci Rep 7(1):1900. https://doi.org/10.1038/s41598-017-01964-1 CrossRefPubMedPubMedCentral

19.

Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440–446. https://doi.org/10.1158/0008-5472.CAN-09-1947 CrossRef

20.

Qin Y, Qi N, Tang Y, He J, Li X, Gu F, Zou S (2015) Isolation and identification of a high molecular weight protein in sow milk. Animal 9(5):847–854. https://doi.org/10.1017/S1751731114003280 CrossRefPubMed

21.

Palma JP, Rodriguez LE, Bontcheva-Diaz VD, Bouska JJ, Bukofzer G, Colon-Lopez M, Guan R, Jarvis K, Johnson EF, Klinghofer V, Liu X, Olson A, Saltarelli MJ, Shi Y, Stavropoulos JA, Zhu GD, Penning TD, Luo Y, Giranda VL, Rosenberg SH, Frost DJ, Donawho CK (2008) The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 28(5A):2625–2635PubMed

22.

Brookes S, Gagrica S, Sanij E, Rowe J, Gregory FJ, Hara E, Peters G (2015) Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence. Cell Cycle 14(8):1164–1173. https://doi.org/10.1080/15384101.2015.1010866 CrossRefPubMedPubMedCentral

23.

Vermes I, Haanen C, Reutelingsperger C (2000) Flow cytometry of apoptotic cell death. J Immunol Methods 243(1–2):167–190CrossRefPubMed

24.

He BC, Gao JL, Luo X, Luo J, Shen J, Wang L, Zhou Q, Wang YT, Luu HH, Haydon RC, Wang CZ, Du W, Yuan CS, He TC, Zhang BQ (2011) Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/ss-catenin signaling. Int J Oncol 38(2):437–445. https://doi.org/10.3892/ijo.2010.858 CrossRefPubMed

25.

Xiao K, Luo J, Fowler WL, Li Y, Lee JS, Xing L, Cheng RH, Wang L, Lam KS (2009) A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials 30(30):6006–6016. https://doi.org/10.1016/j.biomaterials.2009.07.015 CrossRefPubMedPubMedCentral

26.

Zhao E, Ilyas G, Cingolani F, Choi JH, Ravenelle F, Tanaka KE, Czaja MJ (2017) Pentamidine blocks hepatotoxic injury in mice. Hepatology 66(3):922–935. https://doi.org/10.1002/hep.29244 CrossRefPubMedPubMedCentral

27.

Hammond WA, Swaika A, Mody K (2016) Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol 8(1):57–84. https://doi.org/10.1177/1758834015614530 CrossRefPubMedPubMedCentral

28.

Bradshaw-Pierce EL, Pitts TM, Kulikowski G, Selby H, Merz AL, Gustafson DL, Serkova NJ, Eckhardt SG, Weekes CD (2013) Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PLoS One 8(3):e58089. https://doi.org/10.1371/journal.pone.0058089 CrossRefPubMedPubMedCentral

29.

Tsukihara H, Nakagawa F, Sakamoto K, Ishida K, Tanaka N, Okabe H, Uchida J, Matsuo K, Takechi T (2015) Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep 33(5):2135–2142. https://doi.org/10.3892/or.2015.3876 CrossRefPubMedPubMedCentral

30.

Vormoor B, Curtin NJ (2014) Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma. Curr Opin Oncol 26(4):428–433. https://doi.org/10.1097/CCO.0000000000000091 CrossRefPubMedPubMedCentral

31.

Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72(21):5588–5599. https://doi.org/10.1158/0008-5472.CAN-12-2753 CrossRefPubMedPubMedCentral

32.

Noll DM, Mason TM, Miller PS (2006) Formation and repair of interstrand cross-links in DNA. Chem Rev 106(2):277–301. https://doi.org/10.1021/cr040478b CrossRefPubMedPubMedCentral

33.

Nicolay NH, Ruhle A, Perez RL, Trinh T, Sisombath S, Weber KJ, Schmezer P, Ho AD, Debus J, Saffrich R, Huber PE (2016) Mesenchymal stem cells exhibit resistance to topoisomerase inhibition. Cancer Lett 374(1):75–84. https://doi.org/10.1016/j.canlet.2016.02.007 CrossRefPubMed

34.

Abdou I, Poirier GG, Hendzel MJ, Weinfeld M (2015) DNA ligase III acts as a DNA strand break sensor in the cellular orchestration of DNA strand break repair. Nucleic Acids Res 43(2):875–892. https://doi.org/10.1093/nar/gku1307 CrossRefPubMed

35.

Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, Miller GM, Caufield W, Freeman BB 3rd, Bahrami A, Pappo A, Wu J, Loh A, Karlstrom A, Calabrese C, Gordon B, Tsurkan L, Hatfield MJ, Potter PM, Snyder SE, Thiagarajan S, Shirinifard A, Sablauer A, Shelat AA, Dyer MA (2014) Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep 9(3):829–841. https://doi.org/10.1016/j.celrep.2014.09.028 CrossRefPubMedPubMedCentral

36.

Cao TP, Kim JS, Woo MH, Choi JM, Jun Y, Lee KH, Lee SH (2016) Structural insight for substrate tolerance to 2-deoxyribose-5-phosphate aldolase from the pathogen Streptococcus suis. J Microbiol 54(4):311–321. https://doi.org/10.1007/s12275-016-6029-4 CrossRefPubMed

37.

Strumberg D, Pilon AA, Smith M, Hickey R, Malkas L, Pommier Y (2000) Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff. Mol Cell Biol 20(11):3977–3987CrossRefPubMedPubMedCentral

38.

Malanga M, Althaus FR (2004) Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing. J Biol Chem 279(7):5244–5248. https://doi.org/10.1074/jbc.C300437200 CrossRefPubMed

39.

Sugimura K, Takebayashi S, Taguchi H, Takeda S, Okumura K (2008) PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA. J Cell Biol 183(7):1203–1212. https://doi.org/10.1083/jcb.200806068 CrossRefPubMedPubMedCentral

40.

Marechal A, Zou L (2013) DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol 5(9). https://doi.org/10.1101/cshperspect.a012716

41.

Kaku Y, Tsuchiya A, Kanno T, Nishizaki T (2015) Irinotecan induces cell cycle arrest, but not apoptosis or necrosis, in Caco-2 and CW2 colorectal cancer cell lines. Pharmacology 95(3–4):154–159. https://doi.org/10.1159/000381029 CrossRefPubMed

42.

Williams AB, Schumacher B (2016) p53 in the DNA-damage-repair process. Cold Spring Harb Perspect Med 6(5). https://doi.org/10.1101/cshperspect.a026070

43.

Origanti S, Cai SR, Munir AZ, White LS, Piwnica-Worms H (2013) Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells. Oncogene 32(5):577–588. https://doi.org/10.1038/onc.2012.84 CrossRefPubMed

44.

Abd Elmageed ZY, Naura AS, Errami Y, Zerfaoui M (2012) The poly(ADP-ribose) polymerases (PARPs): new roles in intracellular transport. Cell Signal 24(1):1–8. https://doi.org/10.1016/j.cellsig.2011.07.019 CrossRefPubMed

45.

Davidson D, Wang Y, Aloyz R, Panasci L (2013) The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. Investig New Drugs 31(2):461–468. https://doi.org/10.1007/s10637-012-9886-7 CrossRef

46.

Lieberman HB, Panigrahi SK, Hopkins KM, Wang L, Broustas CG (2017) p53 and RAD9, the DNA damage response, and regulation of transcription networks. Radiat Res 187(4):424–432. https://doi.org/10.1667/RR003CC.1 CrossRefPubMedPubMedCentral

47.

Rosado MM, Bennici E, Novelli F, Pioli C (2013) Beyond DNA repair, the immunological role of PARP-1 and its siblings. Immunology 139(4):428–437. https://doi.org/10.1111/imm.12099 CrossRefPubMedPubMedCentral

48.

Lee YC, Lee CH, Tsai HP, An HW, Lee CM, Wu JC, Chen CS, Huang SH, Hwang J, Cheng KT, Leiw PL, Chen CL, Lin CM (2015) Targeting of topoisomerase I for prognoses and therapeutics of camptothecin-resistant ovarian cancer. PLoS One 10(7):e0132579. https://doi.org/10.1371/journal.pone.0132579 CrossRefPubMedPubMedCentral

49.

Huang K, Zhang J, O'Neill KL, Gurumurthy CB, Quadros RM, Tu Y, Luo X (2016) Cleavage by caspase 8 and mitochondrial membrane association activate the BH3-only protein bid during TRAIL-induced apoptosis. J Biol Chem 291(22):11843–11851. https://doi.org/10.1074/jbc.M115.711051 CrossRefPubMed

50.

McIlwain DR, Berger T, Mak TW (2015) Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol 7(4). https://doi.org/10.1101/cshperspect.a026716

51.

Mao D, Qiao L, Lu H, Feng Y (2016) B-cell translocation gene 3 overexpression inhibits proliferation and invasion of colorectal cancer SW480 cells via Wnt/beta-catenin signaling pathway. Neoplasma 63(5):705–716. https://doi.org/10.4149/neo_2016_507 CrossRefPubMed

52.

Melling N, Kowitz CM, Simon R, Bokemeyer C, Terracciano L, Sauter G, Izbicki JR, Marx AH (2016) High Ki67 expression is an independent good prognostic marker in colorectal cancer. J Clin Pathol 69(3):209–214. https://doi.org/10.1136/jclinpath-2015-202985 CrossRefPubMed

53.

Al-Ali H, Ding Y, Slepak T, Wu W, Sun Y, Martinez Y, Xu XM, Lemmon VP, Bixby JL (2017) The mTOR substrate S6 kinase 1 (S6K1) is a negative regulator of axon regeneration and a potential drug target for central nervous system injury. J Neurosci 37(30):7079–7095. https://doi.org/10.1523/JNEUROSCI.0931-17.2017 CrossRefPubMedPubMedCentral

54.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M (2014) The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 53(7):852–864. https://doi.org/10.3109/0284186X.2014.895036 CrossRefPubMed

55.

Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, Li S (2015) Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res 21(4):899–906. https://doi.org/10.1158/1078-0432.CCR-14-0894 CrossRefPubMed

Title: Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib
Authors: Titto Augustine
Radhashree Maitra
Jinghang Zhang
Jay Nayak
Sanjay Goel
Publication date: 01-10-2019
Publisher: Springer US
Keywords: Colorectal Cancer
Colorectal Cancer
Published in: Investigational New Drugs / Issue 5/2019
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-018-00717-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 5/2019

MiR-181a, a new regulator of TGF-β signaling, can promote cell migration and proliferation in gastric cancer

Modulator of the PI3K/Akt oncogenic pathway affects mTOR complex 2 in human adenocarcinoma cells

Human antigen R and drug resistance in tumors

MICONIDINE acetate, a new selective and cytotoxic compound with synergic potential, induces cell cycle arrest and apoptosis in leukemia cells

The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer

Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo

Keynote webinar | Spotlight on antibody–drug conjugates in cancer